Science · Open for opinions
Will the FDA or Anvisa approve a clinical trial for epigenetic editing against hepatitis B by October 31, 2026?
Considers regulatory authorizations for clinical trials of epigenetic silencing published between 09/21 and 10/31/2026. 58 opinions, 66% No
- Yes — 34%
- No — 66%
Deadline: October 31, 2026 at 11:59 PM UTC · 58 opinions
Resolution rules
Considers regulatory authorizations for clinical trials of epigenetic silencing published between 09/21 and 10/31/2026.
Source: www.nature.com
Frequently asked questions about this event
How is this event resolved?
Janela de apuração: de 21/09/2026 (00:00, horário de Brasília) até 31/10/2026 (23:59). Resolve como 'Sim' se a FDA (EUA) ou a Anvisa autorizar formalmente protocolo de ensaio clínico em humanos para terapia de edição epigenética contra hepatite B até 31/10/2026, conforme registro público em fda.gov, ClinicalTrials.gov ou Diário Oficial da União. Caso contrário, resolve como 'Não'.
How are points scored?
Points depend on the share of votes your side had when you gave your opinion. Being right earns 100 minus that share. Being wrong costs that share.
Right now No has 66% of the votes: an opinion on it that turns out right earns about 34 points, a wrong one costs about 66.